期刊
PHARMACOLOGY
卷 71, 期 3, 页码 162-168出版社
KARGER
DOI: 10.1159/000077451
关键词
cabergoline; nerve growth factor; brain-derived neurotrophic factor; glial cell line-derived neurotrophic factor; astrocytes; Parkinson's disease
Neuroprotection is the primary concern in patients with newly diagnosed Parkinson's disease. The D-2/weak D-1 dopamine agonist cabergoline elicits neuroprotection by antioxidation and scavenging free radicals, and may protect neurons by up-regulating endogenous neurotrophic factors synthesis in the brain. In primary cultured mouse astrocytes, cabergoline 37 mumol/l immediately elevated concentrations of nerve growth factor, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor ( GDNF) in culture medium, reaching 9.9-, 2.6- and 30-fold, respectively, of control levels at 16 h. Relative mRNA levels were 3.0-, 1.5- and 1.9-fold, respectively, of controls at 3 h. These effects may be mediated partly by the dopamine D-2 receptor. Cabergoline may be a good candidate for an inducer of GDNF, which may have neuroprotective and neurorestorative properties in dopaminergic nigral neurons. Copyright (C) 2004 S. Karger AG, Basel.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据